AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.6475
+0.0579 (9.82%)
Jun 4, 2025, 1:58 PM - Market open
Company Description
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.
The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
AEON Biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Robert Bancroft |
Contact Details
Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States | |
| Phone | 949 354 6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00775E102 |
| ISIN Number | US00791X1000 |
| Employer ID | 85-3940478 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Bancroft | President, Chief Executive Officer and Director |
| Alex Wilson | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Jennifer Sy | Chief Accounting Officer and Principal Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2025 | SCHEDULE 13G | Filing |
| May 20, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |